Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2016 -- G1 Therapeutics, Inc., a clinical-stage oncology company, announced today that Chief Executive Officer Mark Velleca, MD, PhD, will present a company overview at the 18th Annual BIO CEO & Investor Conference. The presentation will take place on Tuesday, February 9 at 1:30 p.m. ET at the Waldorf Astoria New York in New York City.
For additional information on the conference, visit: http://www.bio.org/events/conferences/bio-ceo-investor-conference.
About G1 Therapeutics, Inc.
G1 Therapeutics is a clinical-stage oncology company developing novel, small-molecule therapies that address significant unmet needs in patients with cancer. The company is advancing G1T28, a first-in-class drug candidate, and G1T38, a potential best-in-class compound, in multiple oncology indications. G1 is privately held and based in Research Triangle Park, NC.
Visit www.g1therapeutics.com for more information.
Contact: Mark Velleca, MD, PhD G1 Therapeutics 919-213-9838 [email protected] Media: Laura Bagby 6 Degrees Communications 312-448-8098 [email protected]
